Risk of HBV reactivation during therapies for HCC: A systematic review. Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV, et al. Hepatology 2022;75:1257-1274.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV, et al. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2022;75:1257-1274.
PMID: 34918361